Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

Tiziana Life Sciences (TLSA) announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access ...

To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement or stability of disease within 6 months ...

The effect of levetiracetam, an antiseizure therapy, on high-frequency oscillation in patients with Alzheimer’s disease as ...

CNW/ - Feldan Therapeutics ("Feldan"), a clinical-stage pharmaceutical company specialized in the development of treatments based on intracellular delivery ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the ...

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...

Five oculopharyngeal muscular dystrophy (OPMD) patients have now been treated with the gene therapy candidate BB-301 in a ...

Reflecting these positive developments, Goldman Sachs has raised its 12-month target price for Everest Medicines to HK$48.32, nearly doubling from the previous HK$24.50. The upgrade factors in ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...